Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Publication year range
1.
Antibiot Khimioter ; 49(4): 16-20, 2004.
Article in Russian | MEDLINE | ID: mdl-15460018

ABSTRACT

The study was aimed at design of new dosage forms of doxorubicin (films, erythrocyte vehicles) for correction of its hepatotoxic, prooxidant and immunosuppressory effects. The experiments were performed on Wistar rats with the use of doxorubicin of Lens-Pharm (Moscow) and auxiliary substances meeting the requirements of the standards. Technology for preparation of doxorubicin-entrapped films was developed and the optimal polymer for the vehicle was recommended, i.e. oxypropylmethylcellulose Methocel 65 Hg 50 providing preservation of the antimicrobial activity. Conditions for storage of the antibiotic-entrapped films were determined. The main qualitative indices of the antibiotic-entrapped films were shown to be stable during the storage for 12 months. Erythrocyte-vehicles with entrapped doxorubicin were prepared. Antibiotic-free erythrocyte vehicles were found to preserve their ability to entrap doxorubicin for 9 days and the doxorubicin-entrapped erythrocyte vehicles were stable for 48 hours. A procedure for spectrophotometric qualitative evaluation of doxorubicin entrapping into the films and erythrocyte vehicles was developed. It was observed that administration of doxorubicin immobilized in the films had a stabilizing effect on the immunity status, the level of lipid peroxidation, the potency of the antioxidant system, cytolysis and cholestasis. Administration of the doxorubicin entrapped in the erythrocyte vehicles stimulated the body immune response, normalized the indices of the lipid peroxidation--antioxidant system and the state of the hepatic cells in the laboratory animals infected by staphylococci.


Subject(s)
Doxorubicin/administration & dosage , Drug Carriers , Methylcellulose , Animals , Doxorubicin/therapeutic use , Drug Evaluation, Preclinical , Drug Stability , Erythrocyte Membrane , Hepatocytes/metabolism , Immunosuppression Therapy , Injections, Intramuscular , Lipid Peroxidation , Pharmaceutic Aids , Rats , Rats, Wistar , Staphylococcal Infections/drug therapy , Staphylococcus aureus , Time Factors
2.
Antibiot Khimioter ; 49(8-9): 21-4, 2004.
Article in Russian | MEDLINE | ID: mdl-15727141

ABSTRACT

The aim of the study was to lower the immunosuppressory, prooxidant and hepatotoxic effects of rifampicin and cephalexin by their immobilization in erythrocyte vehicles. The experiments were performed on Wistar rats with the use of rifampicin, cephalexin and lysozyme (ZAO Ferane) and hemodes (6% aqueous saline solution of low molecular polyvinylpyrrolidone, mol. wt. 12600+/-2700). Rifampicin- and cephalexin-entrapped erythrocytes were prepared. Spectrophotometric procedures for quantitative assay of the immobilized antibiotics were developed. The impact of the solution concentration and incubation time on the level of the antibiotic entrapping was studied. The erythrocyte vehicles were shown to be able to entrap the antibiotics for 9 days and to preserve their stability for 24 hours. It was observed that the increase of the immunosuppressory, prooxidant and hepatotoxic effects of the antibiotics administered without the vehicles to the laboratory animals infected by staphylococci was dose-dependent. The use of the antibiotics entrapped in the erythrocyte vehicles stimulated the immune reactivity of the animals and normalized the indices of lipid peroxidation, the antioxidant system, cytolysis and cholestasis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Cephalexin/administration & dosage , Drug Carriers , Erythrocytes , Rifampin/administration & dosage , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/therapeutic use , Animals , Anti-Bacterial Agents/therapeutic use , Antioxidants/administration & dosage , Antioxidants/therapeutic use , Cephalexin/therapeutic use , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Hepatocytes/metabolism , Injections, Intramuscular , Liver/drug effects , Liver/metabolism , Lymphocyte Count , Rats , Rats, Wistar , Rifampin/therapeutic use , Spleen/immunology , Staphylococcus aureus
SELECTION OF CITATIONS
SEARCH DETAIL